Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.
Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually
Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.